Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,246 across all filing types
Latest filing 2019-11-05 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 100% confidence The document text contains only placeholders for omitted pictures and no substantive text or financial data. The true document length is only 169 characters, indicating it is extremely short and contains no report content. There is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2019-11-05 English
Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Monday, November 11, 2019 at the registered office of the ....
Regulatory Filings Classification · 95% confidence The document is a notice dated November 5, 2019, from Bliss GVS Pharma Ltd. announcing a Board Meeting scheduled for November 11, 2019. The purpose of the meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2019. The document references regulatory compliance with SEBI regulations and mentions the closure of the trading window for insiders. It is essentially a formal announcement of the upcoming board meeting and the financial results to be approved, not the financial results report itself. The document length is about 11,854 characters, but the content is clearly an announcement of a meeting and financial results approval, not the results or report. Therefore, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and notice, rather than an Interim Report (IR) or Earnings Release (ER).
2019-11-05 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is extremely short (383 characters) and contains only address and listing department information for stock exchanges (NSE and BSE). There is no financial data, report content, or detailed information. It appears to be a brief notice or communication likely related to regulatory or listing matters, but not a full report or announcement of voting results, dividends, or management changes. Given the brevity and lack of substantive content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-11-02 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2019 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Regulatory Filings Classification · 95% confidence The document is a formal letter titled 'Intimation of Board Meeting' addressed to the stock exchange (BSE Limited). It informs about the scheduled Board Meeting to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2019. The letter also mentions the closure of the trading window for insiders around the announcement date. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is a notification about an upcoming board meeting and the expected approval of financial results, not the results or report itself. The document length is short (2620 characters), and it serves as an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories like Interim Report or Earnings Release.
2019-11-02 English
Please find enclosed herewith the half yearly compliance certificate issued by Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half year ended September 30, 2019. It is a compliance certificate from a Company Secretary in Practice regarding share transfer deeds and related processes. The document does not contain financial statements or detailed financial analysis but is a regulatory compliance certificate. It is not an annual or interim report, earnings release, or any other financial report. It is also not an announcement of a report but the certificate itself. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications and compliance documents that do not fit other categories.
2019-10-24 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchange surveillance officials responding to their query about unusual price movement in the company's shares. It clarifies that there is no material information affecting the share price and that the company complies with disclosure regulations. The document is a regulatory communication clarifying price movement, not a financial report, earnings release, or any other detailed filing. It is short (2476 characters) and serves as a regulatory filing or compliance communication. Therefore, it fits best under Regulatory Filings (RNS).
2019-10-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.